Navigation Links
Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
Date:10/22/2007

WARRENDALE, Pa., Oct. 22 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its newly enhanced Allient(R) Sorbent Hemodialysis System in chronic and acute hemodialysis applications. The new Allient System features improvements in ease of manufacturing, service and user-friendliness. In preparation for the Allient System commercialization, Renal Solutions is also launching its SMARRT(TM) (Sorbent Management for Advanced Renal Replacement Therapy) platform and campaign, which will introduce the benefits of advanced sorbent therapy to the renal community.

SMARRT therapy utilizes a gentle, patient-driven technology backed by over 6 million treatments. It enables short, standard or extended duration hemodialysis therapy using just 1.5 gallons (6 liters) of drinking water. The small dialysate quantity made possible by sorbent technology provides an inherent volume safety not possible with conventional hemodialysis technology. At the same time, it creates a dialysate flow rate of up to 400 ml/min., enabling the provision of highly effective dialysis. Advanced sorbent cartridges contain specialized sorbent compounds that regenerate fresh, high purity dialysate, eliminating the need for complex and costly water purification systems.

The Allient System will be the first dialysis system to bring SMARRT technology to the market, opening new treatment options to dialysis professionals and patients. The Allient System provides multiple treatment options without the need for an independent water purification system, batch production of dialysate, or large volumes of packaged sterile fluid. In addition to the sorbent cartridge benefits, the Allient System's revolutionary Pulsar(TM) Blood Pump provides expanded safety and versatility advantages as c
'/>"/>

SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Renal problem alleviated
2. Increase in renal problems
3. Effect of drug on Renal Cancer
4. Renal problem increased
5. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
6. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
7. A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma
8. Negative Impact Of Hepatitis C Infection In Renal Transplant Recipients
9. Clinical Renal Trails Do Not Have Sufficient Women Participants
10. Adrenal Suppression not predicted by inhaled corticosteroids
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Is this the beginning of the end of plant breeding 3F 8759 1Is this the beginning of the end of plant breeding 3F 8759 2Is this the beginning of the end of plant breeding 3F 8759 3Brookdale Announces Completion of Follow On Offering 48237 1Brookdale Announces Completion of Follow On Offering 48237 2Brookdale Announces Completion of Follow On Offering 48237 3Brookdale Announces Completion of Follow On Offering 48237 4Brookdale Announces Completion of Follow On Offering 48237 5Colorado Gastroenterology Chooses Qqests TimeForce Payroll Services 48234 1Colorado Gastroenterology Chooses Qqests TimeForce Payroll Services 48234 2